Consensus EyePoint, Inc.

Stocks

EYPT

US30233G2093

Pharmaceuticals

Real-time Estimate Cboe BZX 18:37:26 01/10/2026 +04			5-day change	1st Jan Change
3.290 ^USD	+0.61%		-8.52%	-81.72%

09-15	EyePoint, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 07:00 AM
09-09	EyePoint, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 08:00 AM

Evolution of the Average Target: EyePoint, Inc.

Evolution of the Target Price: EyePoint, Inc.

Changes in Analyst Recommendations: EyePoint, Inc.

a64.ouh7u5N5m9j8OQZShutvhalCNDZ3HtBZfK9PKiQNlTw.y7s91tES17C3WF48wa457JslbV5Bcb4DGOc7fHBHoETpmAnd0kzesYZqUw~6730064feb25b57f73a5fd11cef86a7c

Analysts' recommendations: EyePoint, Inc.

09-02	TD Cowen Downgrades EyePoint Pharmaceuticals to Hold From Buy, Adjusts PT to $4 From $20	MT
08-18	EyePoint Faces Regulatory Uncertainty After Lugano Trial Miss, RBC Capital Markets Says	MT
08-18	Chardan Downgrades EyePoint Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $5 From $65	MT
08-18	RBC Downgrades EyePoint to Sector Perform From Outperform, Cuts Price Target to $5 From $37, Keeps Speculative Risk	MT
08-18	HC Wainwright Downgrades EyePoint Pharmaceuticals to Neutral From Buy	MT
08-17	JPMorgan Downgrades EyePoint Pharmaceuticals to Neutral From Overweight	MT
08-04	Ocular Therapeutix's NDA Plans for Axpaxli in Wet AMD Remain on Track, RBC Says	MT
07-29	Mizuho Raises Price Target on EyePoint Pharmaceuticals to $39 From $36, Keeps Outperform Rating	MT
07-16	Stifel Initiates EyePoint Pharmaceuticals at Buy With $40 Price Target	MT
07-01	Chardan Boosts Price Target on EyePoint Pharmaceuticals to $65 From $29, Keeps Buy Rating	MT
05-07	RBC Capital Adjusts EyePoint Pharmaceuticals PT to $37 From $39, Maintains Outperform Speculative-Risk Rating	MT
03-05	Chardan Raises Price Target on EyePoint Pharmaceuticals to $29 From $27, Keeps Buy Rating	MT
11-06	RBC Raises Price Target on EyePoint Pharmaceuticals to $39 From $28, Keeps Outperform, Speculative Risk	MT
15/10/25	Cooking oil, hot markets
14/08/25	Mizuho Adjusts Price Target on EyePoint Pharmaceuticals to $28 From $26, Maintains Outperform Rating	MT
17/06/25	RBC Capital Initiates EyePoint Pharmaceuticals at Outperform With $28 Price Target	MT
16/05/25	Mizuho Cuts Price Target on EyePoint Pharmaceuticals to $26 From $30, Keeps Outperform Rating	MT
07/01/25	Citigroup Initiates EyePoint Pharmaceuticals at Buy With $33 Price Target	MT
16/10/24	Scotiabank Initiates EyePoint Pharmaceuticals at Sector Outperform With $18 Price Target	MT
28/08/24	Jefferies Initiates EyePoint Pharmaceuticals at Buy	MT
04/06/24	JPMorgan Adjusts EyePoint Pharmaceuticals Price Target to $32 From $35, Maintains Overweight Rating	MT
08/05/24	Baird Adjusts Price Target on EyePoint Pharmaceuticals to $38 From $46, Keeps Outperform Rating	MT
07/05/24	Chardan Research Adjusts EyePoint Pharmaceuticals' PT to $28 From $39 After Data From PAVIA Study of Duravyu Disappoint; Keeps Buy Rating	MT
07/05/24	Mizuho Securities Cuts Price Target on EyePoint Pharmaceuticals to $30 From $39, Maintains Buy Rating	MT
15/02/24	Mizuho Boosts PT on EyePoint Pharmaceuticals to $39 From $30 Ahead of Q4 2023 Earnings Announcement, Keeps Buy Rating	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	EYEPOINT, INC.					+692.33%
	ELI LILLY AND COMPANY					+14.84%
	JOHNSON & JOHNSON					+5.49%
	ABBVIE INC.					+6.6%
	MERCK & CO., INC.					+7.19%
	ROCHE HOLDING AG					+7.52%
	NOVARTIS AG					+5.92%
	ASTRAZENECA PLC					+29.21%
	AMGEN INC.					-7.25%
	GILEAD SCIENCES, INC.					+6.44%
	Average					+76.83%
	Weighted average by Cap.					+9.48%